Literature DB >> 28217919

Serious Infection Rates Among Children With Systemic Lupus Erythematosus Enrolled in Medicaid.

Linda T Hiraki1, Candace H Feldman2, Francisco M Marty2, Wolfgang C Winkelmayer3, Hongshu Guan2, Karen H Costenbader2.   

Abstract

OBJECTIVE: To investigate the nationwide prevalence and incidence of serious infections among children with systemic lupus erythematosus (SLE) enrolled in Medicaid, the US health insurance program for low-income patients.
METHODS: From Medicaid claims (2000-2006) we identified children ages 5 to <18 years with SLE (≥3 International Classification of Diseases, Ninth Revision [ICD-9] codes of 710.0, each >30 days apart) and lupus nephritis (LN; ≥2 ICD-9 codes for kidney disease on/after SLE codes). From hospital discharge diagnoses, we identified infection subtypes (bacterial, fungal, and viral). We calculated incidence rates (IRs) per 100 person-years, mortality rates, and hazard ratios adjusted for sociodemographic factors, medications, and preventive care.
RESULTS: Among 3,500 children with identified SLE, 1,053 serious infections occurred over 10,108 person-years; the IR was 10.42 per 100 person-years (95% confidence interval [95% CI] 9.80-11.07) among all those with SLE and 17.65 per 100 person-years (95% CI 16.29-19.09) among those with LN. Bacterial infections were most common (87%, of which 39% were bacterial pneumonias). In adjusted models, African Americans and American Indians had higher rates of infections compared with white children, and those with comorbidities or receiving corticosteroids had higher infection rates than those without. Males had lower rates of serious infections compared to females. The 30-day postdischarge mortality rate was 4.4%.
CONCLUSION: Overall, hospitalized infections were very common in children with SLE, with bacterial pneumonia being the most common infection. Highest infection risks were among African American and American Indian children, those with LN, comorbidities, and those taking corticosteroids.
© 2017, American College of Rheumatology.

Entities:  

Mesh:

Year:  2017        PMID: 28217919      PMCID: PMC5563276          DOI: 10.1002/acr.23219

Source DB:  PubMed          Journal:  Arthritis Care Res (Hoboken)        ISSN: 2151-464X            Impact factor:   4.794


  22 in total

1.  Veteran's affairs hospital discharge databases coded serious bacterial infections accurately.

Authors:  Sebastian Schneeweiss; Ari Robicsek; Richard Scranton; Dan Zuckerman; Daniel H Solomon
Journal:  J Clin Epidemiol       Date:  2006-12-18       Impact factor: 6.437

2.  End-stage renal disease due to lupus nephritis among children in the US, 1995-2006.

Authors:  Linda T Hiraki; Bing Lu; Steven R Alexander; Tamara Shaykevich; Graciela S Alarcón; Daniel H Solomon; Wolfgang C Winkelmayer; Karen H Costenbader
Journal:  Arthritis Rheum       Date:  2011-07

3.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.

Authors:  M E Charlson; P Pompei; K L Ales; C R MacKenzie
Journal:  J Chronic Dis       Date:  1987

4.  The nature and outcome of infection in systemic lupus erythematosus.

Authors:  D D Gladman; F Hussain; D Ibañez; M B Urowitz
Journal:  Lupus       Date:  2002       Impact factor: 2.911

5.  Infections in systemic lupus erythematosus: a prospective and controlled study of 110 patients.

Authors:  X Bosch; A Guilabert; L Pallarés; R Cerveral; M Ramos-Casals; A Bové; M Ingelmo; J Font
Journal:  Lupus       Date:  2006       Impact factor: 2.911

6.  Major infections in a cohort of 120 patients with juvenile-onset systemic lupus erythematosus.

Authors:  Patrícia Costa-Reis; Simona Nativ; Josephine Isgro; Teresa Rodrigues; Cagri Yildirim-Toruner; Amy Starr; Lisa Saiman; Lisa Imundo; Andrew Eichenfield
Journal:  Clin Immunol       Date:  2013-09-02       Impact factor: 3.969

7.  Prevalence, incidence, and demographics of systemic lupus erythematosus and lupus nephritis from 2000 to 2004 among children in the US Medicaid beneficiary population.

Authors:  Linda T Hiraki; Candace H Feldman; Jun Liu; Graciela S Alarcón; Michael A Fischer; Wolfgang C Winkelmayer; Karen H Costenbader
Journal:  Arthritis Rheum       Date:  2012-08

8.  Epidemiology and sociodemographics of systemic lupus erythematosus and lupus nephritis among US adults with Medicaid coverage, 2000-2004.

Authors:  Candace H Feldman; Linda T Hiraki; Jun Liu; Michael A Fischer; Daniel H Solomon; Graciela S Alarcón; Wolfgang C Winkelmayer; Karen H Costenbader
Journal:  Arthritis Rheum       Date:  2013-03

Review 9.  Infectious complications in SLE after immunosuppressive therapies.

Authors:  Insoo Kang; Sung Hwan Park
Journal:  Curr Opin Rheumatol       Date:  2003-09       Impact factor: 5.006

10.  Severe infections in patients with lupus nephritis treated with immunosuppressants: A retrospective cohort study.

Authors:  Cynthia C Lim; Pei Yun Liu; Hui Zhuan Tan; Peishan Lee; Yok Mooi Chin; Irene Yj Mok; Choong Meng Chan; Jason Cj Choo
Journal:  Nephrology (Carlton)       Date:  2017-06       Impact factor: 2.506

View more
  9 in total

Review 1.  Glucocorticoid treatment in juvenile idiopathic arthritis.

Authors:  Ezgi Deniz Batu
Journal:  Rheumatol Int       Date:  2018-10-01       Impact factor: 2.631

2.  Phenome-wide association study identifies marked increased in burden of comorbidities in African Americans with systemic lupus erythematosus.

Authors:  April Barnado; Robert J Carroll; Carolyn Casey; Lee Wheless; Joshua C Denny; Leslie J Crofford
Journal:  Arthritis Res Ther       Date:  2018-04-10       Impact factor: 5.156

3.  Tuberculosis in Children with Rheumatic Diseases Treated with Biologic Disease-Modifying Anti-Rheumatic Drugs.

Authors:  Chengappa Kavadichanda; M B Adarsh; Sajal Ajmani; Ilaria Maccora; S Balan; A V Ramanan; Vikas Agarwal; Latika Gupta
Journal:  Mediterr J Rheumatol       Date:  2021-12-27

Review 4.  Genetic Polymorphisms and the Clinical Response to Systemic Lupus Erythematosus Treatment Towards Personalized Medicine.

Authors:  Melisa Intan Barliana; Nadiya Nurul Afifah; Riezki Amalia; Laniyati Hamijoyo; Rizky Abdulah
Journal:  Front Pharmacol       Date:  2022-03-18       Impact factor: 5.810

Review 5.  Health disparities in systemic lupus erythematosus-a narrative review.

Authors:  Bilal Hasan; Alice Fike; Sarfaraz Hasni
Journal:  Clin Rheumatol       Date:  2022-07-31       Impact factor: 3.650

6.  Association of low-dose glucocorticoid use and infection occurrence in systemic lupus erythematosus patients: a prospective cohort study.

Authors:  Kazuya Abe; Yuichi Ishikawa; Yasuhiko Kita; Nobuyuki Yajima; Eisuke Inoue; Ken-Ei Sada; Yoshia Miyawaki; Ryusuke Yoshimi; Yasuhiro Shimojima; Shigeru Ohno; Hiroshi Kajiyama; Kunihiro Ichinose; Shuzo Sato; Michio Fujiwara
Journal:  Arthritis Res Ther       Date:  2022-07-28       Impact factor: 5.606

7.  Real-life vaccination coverage in Slovak children with rheumatic diseases.

Authors:  Barbora Balažiová; Zuzana Kuková; Daša Mišíková; Katarína Novosedlíková; Tomáš Dallos
Journal:  Front Pediatr       Date:  2022-08-12       Impact factor: 3.569

Review 8.  Disparities in Lupus and Lupus Nephritis Care and Outcomes Among US Medicaid Beneficiaries.

Authors:  Katherine P Pryor; Medha Barbhaiya; Karen H Costenbader; Candace H Feldman
Journal:  Rheum Dis Clin North Am       Date:  2020-10-29       Impact factor: 2.670

Review 9.  Management of lupus nephritis: a systematic literature review informing the 2019 update of the joint EULAR and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations.

Authors:  Myrto Kostopoulou; Antonis Fanouriakis; Kim Cheema; John Boletis; George Bertsias; David Jayne; Dimitrios T Boumpas
Journal:  RMD Open       Date:  2020-07
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.